Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN  
103.54
-5.75 (-5.26%)
Earnings Announcements

Biohaven Reports Q3 Adjusted Non-GAAP Loss Per Share $1.91

Published: 11/09/2021 12:58 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Biohaven Reports Third Quarter 2021 Financial Results and Recent Business Developments.
Q3 Adjusted Non-GAAP Loss per Share $1.91.
Q3 Loss per Share $2.63.
Q3 Revenue $336 Million.
Biohaven - to Receive From Pfizer Double-digit Royalties on Ex-us Net Sales As Well As Upfront Payment and Milestone Value to Biohaven Up to $1.24 Billion.
Biohaven - Biohaven and Pfizer Announce Strategic Collaboration for Global Commercialization of Nurtec Odt Outside United States.
Q3 Earnings per Share View $-2.40, Revenue View $128.4 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $159.65 Million
Adjusted EPS is expected to be -$2.07

Next Quarter Revenue Guidance is expected to be $158.57 Million
Next Quarter EPS Guidance is expected to be -$2.11

More details on our Analysts Page.